ArticleAnnals of nuclear medicine2026
Baseline FDG PET/CT SUVmax predicts POD24 and progression-free survival in newly diagnosed follicular lymphoma.
Article in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveProgression of disease within 24 months (POD24) identifies high-risk follicular lymphoma (FL) patients with poor outcomes. The prognostic role of baseline 18 F-FDG PET/CT maximum standardized uptake value (SUVmax) in follicular lymphoma (FL) remains uncertain, especially in Asian populations. We examined the association between baseline SUVmax and POD24, as well as its prognostic relevance for progression-free survival (PFS) in newly diagnosed FL patients.
methodsWe retrospectively analyzed 119 newly diagnosed FL patients who underwent baseline 18 F-FDG PET/CT at a single institution between 2012 and 2024. Whole-body SUVmax (the highest SUVmax across all lesions) and site-specific SUVmax values were recorded. Clinical variables, including baseline laboratory parameters and histologic grade, were collected. Receiver operating characteristic (ROC) analysis was used to explore an optimal SUVmax cutoff for POD24. Associations with POD24 and PFS were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.
resultsThe median PFS was 54.3 months, and 24.4% of patients experienced POD24. Higher baseline SUVmax was associated with shorter PFS across evaluated sites. ROC analysis showed modest ability to distinguish patients with POD24, with an optimal whole-body SUVmax cutoff of 14.5. Patients with SUVmax > 14.5 had significantly inferior PFS compared with those with SUVmax ≤ 14.5 (median PFS 38.2 months vs. not reached; log-rank p = 0.024) and a higher incidence of POD24 (44.4% vs. 20.8%). In Cox regression, SUVmax as a continuous variable was associated with PFS (HR 1.065, 95% CI 1.008-1.125, p = 0.025), and SUVmax > 14.5 remained an independent predictor of inferior PFS after multivariable adjustment (HR 2.645, 95% CI 1.082-6.467, p = 0.033).
conclusionsBaseline whole-body SUVmax is an independent predictor of PFS. A ROC-derived cutoff of 14.5 identified patients with inferior PFS and was associated with a higher incidence of POD24 in newly diagnosed FL. Given its simplicity and availability, SUVmax may serve as a practical adjunctive metabolic biomarker to support baseline risk assessment in routine clinical practice.
Indexed as
Identifiers
42159922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.